You are here

  • Home
  • Online First
  • Capecitabine: guaranteed access in adjuvant treatment of breast cancer

Article Text

Article menu
Download PDFPDF
Letter
Capecitabine: guaranteed access in adjuvant treatment of breast cancer
  1. Ana Isabel Cachafeiro Pin1,
  2. Laura Villaverde Piñeiro2,
  3. Cecilia Alejandra Saenz Fernández1,
  4. Ignacio Fernández Sobrado3
  1. 1Pharmacy, Hospital Da Mariña, Burela, Galicia, Spain
  2. 2Pharmacy, Hospital Comarcal de Monforte, Monforte de Lemos, Spain
  3. 3Medical Oncology, University Hospital Lucus Augusti, Lugo, Spain
  1. Correspondence to Ana Isabel Cachafeiro Pin, Pharmacy, Hospital Da Costa, Burela 27880, Spain; ana.isabel.cachafeiro.pin{at}sergas.es

http://dx.doi.org/10.1136/ejhpharm-2022-003650

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    According to the Summary of Product Characteristics,1 capecitabine is indicated for locally advanced or metastatic breast cancer in combination with docetaxel after cytotoxic chemotherapy has failed (the previous treatment must have included an anthracycline), in monotherapy after taxanes and anthracycline have failed, or for patients for whom continuing with anthracycline treatment is not indicated.

    Its adjuvant indication in non-pathological complete response triple-negative breast cancer with residual disease after neoadjuvant therapy and surgery (progression after taxane) was associated with increased …

    View Full Text

    Footnotes

    • Twitter @anaicp, @lvilpin1

    • Contributors AICP designed the study and made primary contributions to data collection. LVP, CASF and IFS assisted with data collection. Guarantor: AICP.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.